On the stock market since 2014, it operates in the world of health and science. It has 90 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 18% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $239.9M would still be left in the vault — a solid cushion for hard times.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
The price looks reasonable next to what the company earns.
Sales are growing strongly for its sector.
The price is looking for direction — no strong breakout, no collapse.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 18% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 99% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 28% a year on average.
There is $315.4M in the vault; even if every debt were paid off, $239.9M would remain.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, TBPH sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: TBPH is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.